Annovis Bio, Inc.
ANVS
$1.57
-$0.07-4.27%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.40% | 3.32% | -23.56% | -33.68% | -30.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.72% | -28.28% | 20.18% | 41.84% | 76.53% |
| Operating Income | 40.72% | 28.28% | -20.18% | -41.84% | -76.53% |
| Income Before Tax | 56.25% | 1.86% | -28.67% | -59.34% | -121.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.25% | 1.86% | -28.67% | -59.34% | -121.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.25% | 1.86% | -28.67% | -59.34% | -121.90% |
| EBIT | 40.72% | 28.28% | -20.18% | -41.84% | -76.53% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 68.27% | 22.27% | -10.72% | -38.01% | -97.38% |
| Normalized Basic EPS | 68.27% | 22.27% | -10.72% | -38.01% | -97.38% |
| EPS Diluted | 45.63% | -5.25% | -44.02% | -74.69% | -97.59% |
| Normalized Diluted EPS | 68.30% | 22.31% | -10.68% | -37.96% | -97.38% |
| Average Basic Shares Outstanding | 34.97% | 30.62% | 22.09% | 17.83% | 10.52% |
| Average Diluted Shares Outstanding | 35.53% | 31.21% | 22.69% | 18.44% | 10.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |